These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26696448)

  • 1. Variations of pharmacokinetics of drugs in patients with cirrhosis.
    Pena MA; Horga JF; Zapater P
    Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations.
    Weersink RA; Burger DM; Hayward KL; Taxis K; Drenth JPH; Borgsteede SD
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):45-57. PubMed ID: 31810397
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.
    Weersink RA; Bouma M; Burger DM; Drenth JP; Hunfeld NG; Kranenborg M; Monster-Simons MH; van Putten SA; Metselaar HJ; Taxis K; Borgsteede SD
    BMJ Open; 2016 Oct; 6(10):e012991. PubMed ID: 27733414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
    Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
    Velenosi TJ; Urquhart BL
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.
    Schlatter C; Egger SS; Tchambaz L; Krähenbühl S
    Drug Saf; 2009; 32(7):561-78. PubMed ID: 19530743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
    Lalonde RL; Wagner JA
    Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjusting dosage of drugs in patients with kidney or liver failure].
    Krähenbühl S
    Schweiz Med Wochenschr; 1998 Feb; 128(6):189-94. PubMed ID: 9540139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.
    Elbekai RH; Korashy HM; El-Kadi AO
    Curr Drug Metab; 2004 Apr; 5(2):157-67. PubMed ID: 15078193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: prescribing medications in patients with cirrhosis - a practical guide.
    Lewis JH; Stine JG
    Aliment Pharmacol Ther; 2013 Jun; 37(12):1132-56. PubMed ID: 23638982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing Studies in Children: A US Regulatory Perspective.
    Roth-Cline M; Nelson RM
    Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICH discussion on pharmacokinetics and toxicokinetics and contributors.
    Ohno Y
    Drug Metab Pharmacokinet; 2013; 28(5):379-82. PubMed ID: 24162438
    [No Abstract]   [Full Text] [Related]  

  • 15. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources?
    Khanal A; Castelino RL; Peterson GM; Jose MD
    Intern Med J; 2014 Jan; 44(1):77-85. PubMed ID: 24112311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A toxicity risk index, an index for warning idiosyncratic drug toxicity.
    Morimoto M; Samizo K; Ohta S; Mizuma T
    J Pharm Sci; 2013 Sep; 102(9):3447-50. PubMed ID: 23666879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug interactions. Mechanisms and clinical relevance].
    Klotz U; Beil W; Gleiter C; Drewelow B; Garbe E; Gillessen A; Mutschler E
    Internist (Berl); 2003 Nov; 44(11):1444-9. PubMed ID: 14689079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of circadian rhythms on the kinetics of drugs in humans.
    Baraldo M
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):175-92. PubMed ID: 18248311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failed Pediatric Drug Development Trials.
    Momper JD; Mulugeta Y; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidance to develop individual dose recommendations for patients on chronic hemodialysis.
    Gotta V; Dao K; Rodieux F; Buclin T; Livio F; Pfister M
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):737-752. PubMed ID: 28447486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.